Resmetirom-mediated reduction in proton density fat fraction and liver volume.
Least squares (LS) mean change from baseline (95% confidence interval (CI)) in PDFF (a) and liver volume (b) at Week 52 in patient subgroups of the open-label 100 mg resmetirom arm. Marker shows median. High SHBG, population (~two-thirds) with ≥120% increase from baseline in SHBG.
